Фармакоэкономика (May 2017)

PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS

  • A. S. Kolbin,
  • I. A. Vilum,
  • М. A. Proskurin,
  • Yu. E. Balykina

DOI
https://doi.org/10.17749/2070-4909.2017.10.1.039-045
Journal volume & issue
Vol. 10, no. 1
pp. 39 – 45

Abstract

Read online

Objectives. To provide a pharmacoeconomic analysis of brentuximab vetodin therapy in relapsed or refractory CD30+ systemic anaplastic large-cell lymphoma in patients over 18 years of age.Methods. Recommendations to carry out a budget impact analysis in theRussian Federation (2016) were used.Results. The analysis covered a period of 3 years. The target population of patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma numbered 345 individuals. The results indicate that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state-guaranteed free medical care will not increase the costs of the treatment in patients with relapsed or refractory CD30+ systemic anaplastic large cell lymphoma.Conclusion. The brentuximab vetodin therapy of relapsed or refractory CD30+ systemic anaplastic large cell lymphoma is an economically reasonable and resource-saving medical modality.

Keywords